Update on the cardiovascular risk in obesity: Endocrine and paracrine role of the adipose tissue

Hellenic Journal of Cardiology

Volumn 52, Issue 4, 2011, Pages 327-336

  Schäfer, Katrin ^a   Konstantinides, Stavros V ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Adipokines; Atherosclerosis; Cytokines; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR; APELIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ABDOMINAL OBESITY; ACUTE CORONARY SYNDROME; ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; ATHEROSCLEROSIS; BODY FAT; CARDIOVASCULAR RISK; CORONARY ARTERY CALCIFICATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GREECE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERLIPIDEMIA; HYPERPLASIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID STORAGE; MACROPHAGE; MORBIDITY; MORTALITY; NEOINTIMA; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; VASCULAR LESION;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; CYTOKINES; ENDOCRINE GLANDS; HUMANS; OBESITY; PARACRINE COMMUNICATION; RISK FACTORS;

EID: 79961163679     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Kapantais E, Tzotzas T, Ioannidis I, et al. First national epidemiological survey on the prevalence of obesity and abdominal fat distribution in Greek adults. Ann Nutr Metab. 2006; 50: 330-338.
2. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab. 2005; 7: 397-405.
3. Haftenberger M, Lahmann PH, Panico S, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2002; 5: 1147-1162.
4. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Epidemiology of overweight and obesity in a Greek adult population: the ATTICA Study. Obes Res. 2004; 12: 1914-1920.
5. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006; 113: 2943-2946.
6. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9: 88.
7. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347: 305-313.
8. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med. 2009; 361: 2252-2260.
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
10. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006; 116: 115-124.
11. Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002; 99: 10730-10735.
12. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131-2135.
13. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of Creactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol. 2005; 46: 1112-1113.
14. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001; 21: 961-967.
15. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001; 21: 968-970.
16. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004; 109: 2818-2825.
17. Turu MM, Slevin M, Matou S, et al. C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol. 2008; 9: 47.
18. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice. Circulation. 2003; 108: 512-515.
19. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 109: 647-655.
20. Danenberg HD, Grad E, Swaminathan RV, et al. Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis. 2008; 201: 85-91.
21. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005; 102: 8309-8314.
22. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990; 10: 493-496.
23. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004; 145: 2273-2282.
24. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008; 117: 605-613.
25. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009; 30: 850-856.
26. Mahabadi AA, Reinsch N, Lehmann N, et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: A segment analysis. Atherosclerosis. 2010; 211: 195-199.
27. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010; 17: 115-130.
28. Lohmann C, Schäfer N, von Lukowicz T, et al. Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis. 2009; 207: 360-367.
29. Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005; 25: 2594-2599.
30. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998; 395: 763-770.
31. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1: 1155-1161.
32. Münzberg H, Myers MG. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci. 2005; 8: 566-570.
33. Heida NM, Leifheit-Nestler M, Schroeter MR, et al. Leptin enhances the potency of circulating angiogenic cells via src kinase and integrin (alpha) vbeta 5: implications for angiogenesis in human obesity. Arterioscler Thromb Vasc Biol. 2010; 30: 200-206.
34. Leyva F, Godsland IF, Ghatei M, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998; 18: 928-933.
35. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. 2009; 53: 167-175.
36. Schroeter MR, Schneiderman J, Schumann B, et al. Expression of the leptin receptor in different types of vascular lesions. Histochem Cell Biol. 2007; 128: 323-333.
37. Schäfer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol. 2004; 24: 112-117.
38. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005; 25: e119-122.
39. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006; 189: 47-60.
40. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci. 2001; 47: 141-150.
41. Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001; 108: 1533-1540.
42. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen YC, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 2002; 287: 1706-1709.
43. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998; 281: 1683-1686.
44. Schroeter MR, Leifheit M, Sudholt P, et al. Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res. 2008; 103: 536-544.
45. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8: 731-737.
46. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-946.
47. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-1295.
48. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts asan endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006; 26: 224-230.
49. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277: 25863-25866.
50. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002; 106: 2767-2770.
51. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296-1301.
52. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100: 2473-2476.
53. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103: 1057-1063.
54. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor- BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105: 2893-2898.
55. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291: 1730-1737.
56. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107: 671-674.
57. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007; 28: 292-298.
58. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002; 22: 173-178.
59. Kockx M, Leenen R, Seidell J, Princen HM, Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost. 1999; 82: 1490-1496.
60. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998; 18: 1-6.
61. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007; 97: 336-342.
62. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997; 78: 656-660.
63. Schäfer K, Müller K, Hecke A, et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003; 23: 2097-2103.
64. Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001; 103: 576-583.
65. Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 2001; 15: 1840-1842.
66. De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem. 2006; 281: 32796-32805.
67. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004; 53: 336-346.
68. Crandall DL, Quinet EM, El Ayachi S, et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol. 2006; 26: 2209-2215.
69. Scroyen I, Jacobs F, Cosemans L, De Geest B, Lijnen HR. Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo. Thromb Haemost. 2009; 101: 388-393.
70. Lijnen HR, Maquoi E, Morange P, et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003; 23: 78-84.
71. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol. 2000; 20: 1150-1154.
72. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307-312.
73. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001; 276: 11252-11256.
74. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003; 88: 4848-4856.
75. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006; 69: 76-85.
76. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471-476.
77. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146: 1764-1771.
78. Heinonen MV, Laaksonen DE, Karhu T, et al. Effect of dietinduced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009; 19: 626-633.
79. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008; 118: 3343-3354.
80. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin- apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. 2007; 171: 1705-1712.
81. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126: 233-240.
82. Hashimoto T, Kihara M, Ishida J, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006; 26: 1267-1272.
83. Zhang Q, Yao F, Raizada MK, O'Rourke ST, Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 2009; 104: 1421-1428.
84. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin- type 1 receptor in blood pressure in vivo. J Biol Chem. 2004; 279: 26274-26279.
85. Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008; 103: 432-440.